For decades, the “LDL-centric” model of heart disease has dominated cardiology: lower your LDL cholesterol (LDL-C) or ApoB particle count, and you lower your risk. A landmark study from the Copenhagen General Population Study at the University of Copenhagen, Denmark, published in Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB), overturns this simple arithmetic. The study reveals that not all ApoB-containing particles are created equal. While a standard LDL particle is like a bullet, a triglyceride-rich VLDL (Very Low-Density Lipoprotein) particle acts more like a “dirty bomb,” carrying a far heavier payload of cholesterol and inflammatory triggers into your arterial walls.
The researchers used advanced Nuclear Magnetic Resonance (NMR) spectroscopy to count and size lipoprotein particles in over 29,000 individuals, following them for a decade. The results were stark: for the exact same number of particles, VLDL was 3.5 times more likely to cause a myocardial infarction (heart attack) than LDL. This challenges the popular longevity narrative that “ApoB is ApoB” regardless of particle type. The findings suggest that “Remnant Cholesterol”—the cholesterol carried in these bloated, triglyceride-rich particles—represents a distinct, high-virulence vector for disease that standard lipid panels (and even standard ApoB testing) may underestimate.
Source:
- Open Access Journal: Per-Particle Triglyceride-Rich Lipoproteins Imply Higher Myocardial Infarction Risk Than Low-Density Lipoproteins: Copenhagen General Population Study
- Impact Evaluation: The impact score of this journal (Arteriosclerosis, Thrombosis, and Vascular Biology) is ~7.4 to 10.5(depending on the year cited), evaluated against a typical high-end range of 0–30+ for specialized cardiovascular journals (and 60+ for elite general science like Nature), therefore this is a High impact specialty journal.
Part 2: The Biohacker Analysis
Study Design Specifications:
- Type: Human Observational / Prospective Cohort Study (Level C Evidence).
- Subjects: 29,039 individuals (nested within a larger cohort of 109,751), all White of Danish descent. 2,309 developed myocardial infarction (MI).
- Lifespan Data: N/A (Study focused on Myocardial Infarction risk, not all-cause mortality lifespan extension).
-
Mechanistic Deep Dive:
- The “Payload” Theory: VLDL particles are physically larger and carry far more cholesterol per particle than LDL. When they penetrate the arterial wall (intima), they deposit a larger mass of sterols.
- Intimal Entrapment: Unlike small LDL particles which may enter and exit the arterial wall, larger VLDL remnants are more prone to getting “stuck” (trapped by glycosaminoglycans), leading to rapid plaque formation.
- Inflammation (CRP): The study reinforces that high triglycerides/VLDL are causally linked to systemic inflammation (elevated CRP), whereas pure LDL elevation is not. This makes VLDL a “double threat”: it provides both the fuel (cholesterol) and the spark (inflammation) for plaque rupture.
Novelty: This paper provides the mathematical quantification of “virulence” per particle. While we knew remnants were bad, we didn’t know how bad. Establishing that one VLDL particle carries the atherogenic risk of ~3.5 LDL particles forces a re-evaluation of patients who have “normal” ApoB but high triglycerides/remnants.
Critical Limitations:
- Observational Nature: This is correlation, not causation. It proves VLDL predicts risk, but not that lowering it per se reduces risk (see the “Pemafibrate Paradox” in Part 5).
- Homogeneous Population: The cohort is exclusively White/Danish; genetic lipid handling (e.g., ApoE variants) differs across ethnicities.
- No Intervention: The study does not test if removing these particles reverses the risk multiplier.
Part 3: Claims & Verification
Claim 1: VLDL particles are more atherogenic per particle than LDL (Risk Ratio ~3.5:1).
- Verification: Confirmed by this cohort. Supported by mechanistic data on “remnant cholesterol” intimal retention.
- Hierarchy: Level C (Strong Cohort Data).
- Translational Gap: None (Human data).
- Consensus Check: Growing consensus, though some experts (e.g., Allan Sniderman) argue that because LDL particles vastly outnumber VLDL particles (often 10:1), LDL remains the primary driver of total risk for most people.
Claim 2: Triglyceride-rich lipoproteins (Remnants) drive inflammation (CRP), whereas LDL does not.
- Verification: Confirmed. Mendelian Randomization studies (Level A/B logic) by the same group (Varbo et al.) and others have consistently shown that genetic variants raising LDL do not raise CRP, but variants raising Remnants/Triglycerides do raise CRP.
- Hierarchy: Level A/B (Genetic causal inference).
- Safety Check: High inflammation is a universal risk factor for aging/frailty.
Claim 3: Standard “Non-HDL” or “ApoB” metrics may mask the specific risk of VLDL.
- Verification: Plausible. If a patient has low total ApoB but the composition is shifted toward VLDL (e.g., insulin resistance/metabolic syndrome), their risk per particle is higher than the standard model predicts.
- Hierarchy: Level C (Logical inference from risk ratios).
Part 4: Actionable Intelligence
Diagnostic Protocol (The “Poor Man’s” NMR): You do not strictly need an expensive NMR LipoProfile to assess this risk.
-
Calculate Remnant Cholesterol:
Total Cholesterol - HDL - LDL = Remnant Cholesterol. - Target: Keep Remnant Cholesterol < 15–20 mg/dL (approx. < 0.5 mmol/L). Above 25 mg/dL indicates significant “dirty bomb” particle presence.
- Advanced: NMR LipoProfile to measure “VLDL-P” (VLDL Particle Number).
Therapeutic Targets (Validation Mode):
-
Compound: Icosapent Ethyl (Prescription Omega-3, e.g., Vascepa).
- Mechanism: Significantly lowers triglycerides and VLDL particles; stabilizes membranes.
- Evidence: REDUCE-IT Trial (Level B) showed 25% risk reduction.
- HED: 4 grams/day (standard human clinical dose).
- Safety: Monitor for Atrial Fibrillation (slight risk increase in trials).
-
Compound: Fibrates (e.g., Pemafibrate, Fenofibrate).
- WARNING: PROMINENT Trial (Level B) failed to show CV benefit despite lowering VLDL/Triglycerides.
- Analysis: This suggests that simply “clearing” VLDL with PPAR-alpha agonists without lowering ApoB may not be sufficient. Do not rely on fibrates alone for life extension.
-
Lifestyle Intervention: Carbohydrate Restriction.
- Mechanism: VLDL is the primary transport for endogenously synthesized fat (from sugar/starch in the liver). Cutting refined carbs/fructose is the most potent non-drug way to slash VLDL particle count.
Safety & Toxicity:
- Liver: High VLDL is a proxy for NAFLD (Fatty Liver). Treating VLDL often requires treating the liver (e.g., via GLP-1 agonists or SGLT2 inhibitors).
- Interactions: High-dose Omega-3s can increase bleeding risk slightly; caution with blood thinners.
Part 5: The Strategic FAQ
1. If VLDL is so dangerous, why did the PROMINENT trial (Pemafibrate) fail? Answer: The PROMINENT trial lowered triglycerides/VLDL (-26%) but did not reduce ApoB (it actually rose slightly). This reinforces that while VLDL is dangerous per particle, if you just convert VLDL into LDL (which fibrates can do) without clearing the ApoB particle entirely, you may not reduce total risk. You must lower the total burden (ApoB), not just shrink the particles. [Confidence: High]
2. Should I stop taking Statins and focus on VLDL? Answer: Absolutely not. Statins are the most effective tool for clearing the sheer volume of ApoB/LDL particles. VLDL is “residual risk”—the risk left over after you’ve crushed your LDL. You treat VLDL on top of statins, not instead of them. [Confidence: High]
3. Does Rapamycin affect VLDL? Answer: It can at higher doses. Rapamycin (mTOR inhibition) when dosed at high levels, frequently, often raises triglycerides and VLDL via reduced LPL activity or altered hepatic synthesis. If you are on a longevity Rapamycin protocol, monitoring Remnant Cholesterol is mandatory. You may need to pair it with a lipid-lowering agent. [Confidence: Medium/High]
4. How does this change my interpretation of a standard lipid panel? Answer: Stop ignoring Triglycerides. Many biohackers dismiss high TGs if their LDL is low. This paper argues that high TGs (a proxy for VLDL) turn your remaining cholesterol particles into “super-atherogenic” vectors. A Triglyceride/HDL ratio > 2.0 is a red flag for VLDL dominance.
5. Is “ApoB” still the king of metrics? Answer: Yes, but it’s a “blunt” king. ApoB sums all atherogenic particles (VLDL + IDL + LDL). It is still the best single predictor of risk, but this paper adds nuance: 100 nanomoles of ApoB as VLDL is worse than 100 nanomoles of ApoB as LDL.
6. What is the Human Equivalent Dose (HED) for lowering VLDL via Omega-3s? Answer: The effective dose in the REDUCE-IT trial was 4g/day of Icosapent Ethyl. Over-the-counter fish oil is often under-dosed and oxidized. To replicate the “VLDL-crushing” effect, you need pharmaceutical-grade EPA at high doses.
7. Can I use Niacin to lower VLDL? Answer: Niacin effectively lowers VLDL and ApoB, but outcome trials (AIM-HIGH, HPS2-THRIVE) failed to show benefit and showed toxicity (insulin resistance). It is generally Level D/E (not recommended) in the modern era compared to safer options like PCSK9 inhibitors or Icosapent Ethyl.
8. Do SGLT2 inhibitors (e.g., Jardiance) help? Answer: Indirectly. By dumping glucose and improving insulin sensitivity, they can lower the hepatic drive to create VLDL. They are excellent “adjunct” longevity drugs for the VLDL-dominant phenotype (metabolic syndrome).
9. What about ApoC-III inhibitors (Volanesorsen/Olezarsen)? Answer: These are the new frontier. They potently slash VLDL/Triglycerides by 60-80%. Olezarsen is currently in late-stage trials and shows massive promise for “familial chylomicronemia” and high CV risk phenotypes. Watch this space.
10. Is this relevant to “Lean Mass Hyper-Responders” (LMHR) on Keto? Answer: Crucially relevant. LMHRs typically have sky-high LDL but low Triglycerides/VLDL. According to this Copenhagen data, their risk per particlemight be lower because they lack the “dirty bomb” VLDL particles, even if their total ApoB is high. However, this is speculative (Level D/E) and remains a subject of intense debate.